Hydrocortisone For Prevention Research Articles

Preventive Care for Children on Chronic Glucocorticoid Therapy Lacks Standardization

Chronic glucocorticoid therapy may be complicated by osteopenia, dyslipidemia, infections, weight gain, and adrenal suppression. Recommendations for screening and preventing these complications include screening for 25-hydroxyvitamin D, pneumococcal vaccine, lipid screening, influenza vaccination, and home prescription of intramuscular hydrocortisone for prevention of adrenal insufficiency. To assess adherence to these recommendations, researchers retrospectively assessed care received by 701 …

Topical hydrocortisone for prevention of postoperative airway irritability following airway surgery

Topical hydrocortisone for prevention of postoperative airway irritability following airway surgery

Role of hydrocortisone in prevention of pain on propofol injection

Background and Objectives:Pain following intravenous injection of propofol continues to be an intriguing problem. None of the commonly used methods completely attenuate the pain. Inflammatory response to propofol contributes to the pain. Role of hydrocortisone in attenuating pain has not been evaluated. This study was conducted to compare the efficacy of lignocaine and hydrocortisone in attenuation of pain following intravenous injection of propofol.Materials and Methods:A prospective randomized double-blind, placebo-controlled study was conducted on 72 adult patients belonging to American Society of Anesthesiologists (ASA) physical status I or II, scheduled to undergo elective surgery. They were randomly assigned to four groups of 18 each. Group NS, group LG, group HC10, and group HC25. The groups received 2 ml normal saline, 2 ml 2% lignocaine, 10 mg/2 ml hydrocortisone, and 25 mg/2 ml hydrocortisone, respectively, as pretreatment. Propofol was injected 30 sec later. A blinded researcher assessed the patient's pain level using a four point verbal rating scale.Results:The four groups were comparable in respect to patient's characteristics. There was no significant difference of hemodynamics changes during propofol induction between all the groups. There was no statistically significant difference in the incidence of pain between patients who received hydrocortisone and the placebo group. The incidence of pain was significantly less in group LG than other three groups.Conclusion:Use of intravenous low dose hydrocortisone pretreatment of the vein does not attenuate pain following propofol injection.

Effect of Single Bolus Injection of Hydrocortisone for Prevention of Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation

Backgrounds: Recent study suggested that steroid can prevent the recurrence of AF. This study evaluated the effect of single bolus injection of hydrocortisone in the prevention of recurrence after PVI. Methods: We analyzed 55 patients (43 male, 55±11 years) with paroxysmal AF who received steroid (steroid group) and 55 sex and age-matched control (44 male, 55±11 years). In the steroid group, intravenous hydrocortisone (100 mg) was given the day of the PVI. Catheter ablation technique included only PVI and cavotricuspid isthmus block. Results: The patients with immediate AF recurrence (within 3 days after the PVI) was 6 (11%) and 4 (8%) in control and steroid groups (p=0.61), respectively. There was no difference in body temperature (p=0.61) and WBC count (p=0.63) during the initial 3 days after ablation between 2 groups. Single bolus injection of hydrocortisone did not decrease AF recurrences between 4 and 30 days after ablation (7% vs 8%, p=0.89). The AF-free rate at 12 months post-ablation was not different between two groups (91% vs 90%, p=0.79 by the log-rank test). Conclusions: Low dose single bolus injection of hydrocortisone shortly after AF ablation was not effective for preventing immediate and AF recurrences during mid-term follow-up period after AF ablation.

Amphotericin B Overdose in Pediatric Patients with Associated Cardiac Arrest

To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population. Treatment is also presented. Hospital. Two infants and three children inpatients receiving amphotericin B. Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B. Cardiac arrest occurred in all patients, and four patients died. A detailed description of the cardiac event is provided for one patient who was on a cardiac monitor during the adverse reaction. Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor). Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias. Amphotericin B overdose can be fatal in children and infants. The presentation in humans appears similar to that in dogs where cardiac arrhythmias occurred at doses of 5-15 mg/kg. Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses. Animal studies are necessary to evaluate this observation and potential disadvantages of hydrocortisone usage.